

Aptima® Chlamydia trachomatis and Aptima® Neisseria gonorrhoeae Assays


- Target different nucleic acid sequences than the Aptima Combo 2® assay.^{1,2}

Chlamydia (CT) and gonorrhea (NG) are two of the most prevalent sexually transmitted infections (STI).³ If left untreated, these infections can cause serious health complications which makes accurate detection critical.^{4,5}


The National Impact of CT and NG

CT is the **most frequently reported** STI in the U.S. with 4 million cases reported.⁴

NG is the **2nd most frequently reported** STI in the U.S. with 1.6 million new infections reported in 2018.⁴



CT and NG infections are often asymptomatic, leading to patients not testing. Therefore, reported cases only capture a fraction of the true burden.^{4,5}



CDC Recommends a NAAT for CT and NG Detection

- The CDC recommends screening sexually active women <25 years annually with a nucleic acid amplification test (NAAT).⁶
- Optimal urogenital specimen for CT and NG NAAT include vaginal swab for women and first-void urine for men.⁶
- A NAAT that targets ribosomal RNA (rRNA) provides a biological advantage compared to assays that detect DNA.⁷

Excellent Sensitivity and Specificity. The Aptima Chlamydia trachomatis and Aptima Neisseria gonorrhoeae assays are single-analyte rRNA based assays that provide excellent performance and an alternative option for detection of CT and NG.^{1,2}

Aptima® Chlamydia trachomatis and Aptima® Neisseria gonorrhoeae Assay Performance

Data comparing performance and specimen inhibition have demonstrated the benefits of the target capture, transcription mediated amplification, and hybridization protection assay technologies used in these assays.^{8,9}

	Aptima Chlamydia trachomatis assay ²		Aptima Neisseria gonorrhoeae assay ¹	
Sample Type	Sensitivity	Specificity	Sensitivity	Specificity
Patient-Collected Vaginal Swab	95.1%	99.5%	—	—
Female Urine	98.1% (PPA*)	99.6% (NPA*)	—	—
Male Urine	98.6%	99.7%	98.4%	99.9%

* Female urine performance was calculated as positive and negative percent agreement, refer to the Aptima Chlamydia trachomatis assay package insert for more details.

Ordering Information

Item	Quantity	Catalog #
Aptima Chlamydia trachomatis Assay Kit (2 Boxes and 1 Controls Kit)	100 Tests	302925
Aptima Neisseria gonorrhoeae Assay Kit (2 Boxes and 1 Controls Kit)	100 Tests	302927

Specimen Collection Available



Visit [Hologic.com/STI](https://www.hologic.com/STI) for more information

References: 1. Aptima Neisseria gonorrhoeae Assay, US package insert, AW-28505-001, Hologic, Inc., 2024. 2. Aptima Chlamydia trachomatis Assay, US package insert, AW-28238-001, Hologic, Inc., 2024. 3. Sexually Transmitted Infections Prevalence, Incidence, and Cost Estimates in the United States, CDC, 2021. Accessed 09 Feb 2024. 4. Chlamydia – CDC Fact Sheet, CDC, 2022. Accessed 09 Feb 2024. 5. Gonorrhea – CDC Fact Sheet, CDC, 2022. Accessed 09 Feb 2024. 6. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):80-82. DOI: <http://dx.doi.org/10.15585/mmwr.mm7004a1>. 7. Chernesky M, et al. High Analytical Sensitivity and Low Rates of Inhibition May Contribute to Detection of Chlamydia trachomatis in Significantly More Women by the APTIMA Combo 2 Assay. *J Clin Microbiol*. 2006;44(2):400-405. doi:10.1128/JCM.44.2.400-405.2006. 8. Chong, S., D. Jang, X. Song, J. Mahony, A. Petrick, P. Barriga, and M. Chernesky. 2003. Specimen Processing and Concentration of Chlamydia trachomatis Added Can Influence False-Negative Rates in the LCx Assay but Not in the Aptima Combo 2 Assay When Testing for Inhibitors. *J. Clin. Microbiol*. 41:778-782. 9. Gaydos, C. A., T. C. Quinn, D. Willis, A. Weissfeld, E. W. Hook, D. H. Martin, D. V. Ferraro, and J. Schachter. 2003. Performance of the Aptima Combo 2 Assay for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Female Urine and Endocervical Swab Specimens. *J. Clin. Microbiol*. 41:304-309.

SS-01554-001 Rev. 001 © 2024 Hologic, Inc. All rights reserved. Hologic, Aptima, Aptima Combo 2, Panther, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, eBroadcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your local Hologic representative or write to diagnostic.solutions@hologic.com.